about
Profitable failure: antidepressant drugs and the triumph of flawed experiments.Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.Substituting placebo for established, effective therapy: why not?The definition of placebo in the informed consent forms of clinical trials.Questioning the methodologic superiority of 'placebo' over 'active' controlled trials.Factors affecting placebo acceptability: deception, outcome, and disease severityWhen ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trialsAccountability and pediatric physician-researchers: are theoretical models compatible with Canadian lived experience?Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls.Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trialChoosing a behavioral therapy platform for pharmacotherapy of substance users.Can psychiatric terminology be translated into legal regulation? The anorexia nervosa example.Why do individuals agree to enrol in clinical trials? A qualitative study of health research participation in Blantyre, MalawiPlacebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better?A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disordersEnhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results.The relevance of empirical research in bioethicsRandomized controlled trials in environmental health research: ethical issues.Environmental health research and the observer's dilemma.What is the best standard for the standard of care in clinical research?The clinical investigator-subject relationship: a contextual approach.Research on environmental health interventions: ethical problems and solutions.Research biopsies in phase I studies: views and perspectives of participants and investigators.End-of-life care in ICU: a practical guide.Ethical issues in Alzheimer's disease: an overview.Ethical review of health systems research in low- and middle-income countries: a conceptual exploration.Equipoise should be amended, not abandoned.Neonatal pain relief and the Helsinki Declaration.Randomized controlled trials: Ethical and scientific issues in the choice of placebo or active control.Dynamic nature of the placebo responseEfficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis.The real problem with equipoise.Comparative effectiveness research for the clinician researcher: a framework for making a methodological design choice.Approaches to interpreting and choosing the best treatments in network meta-analyses.An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study.Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.Physician participation in executions, the morality of capital punishment, and the practical implications of their relationship.Privacy overkill.Primum non nocere and randomised placebo-controlled surgical trials: a dilemma?Rethinking research ethics.
P2860
Q33592406-19987E01-A627-45BF-80BC-AE07C3198050Q33887831-8735F913-7103-4C18-99C5-FAB22A14F2D7Q34273925-E362E933-5ACF-4C5B-94F8-923E908C9D1EQ34571845-B1D73590-C532-4A71-9CE5-64D8C3599A90Q35016839-0164B4AA-8508-44B8-96E0-53CCA4E855EBQ35148120-75CAAB12-080A-41C9-8043-867602D6FF13Q35226105-EC542BED-00BD-4A99-B3EA-E6D93F76485DQ35576536-2D952EB3-1C5A-40D4-A6F0-D991832FABD4Q35609281-9101CA45-EE25-41F9-9C4A-169F44C6BA50Q35716134-04569D74-6702-44D7-A702-4EFBEEEDB550Q35846758-897E8426-41EC-4E1A-9CEE-D73A85C58A38Q35888392-74BC2B78-F297-47F2-B892-09B8A203D79BQ35938143-F7150D72-9A00-4B0C-99E4-3E91F5C6E6EFQ36945380-9EC9FFAB-BB18-4D02-AFEC-7BAC11723C5CQ37014283-988E47A1-7DC0-4041-8E0A-19C522362B6BQ37029169-DD3DF787-C08C-45E7-A31B-2DCADB868F69Q37075748-F886D07F-27DC-4BBA-A370-7742ABCC47ACQ37122087-5B19A7C7-ED2D-4354-9C7E-0BBD876888BFQ37291828-21A7F169-F010-4FB6-8E50-36A9C793BEFCQ37402541-D72948DD-A26B-4BD9-9E4D-A7BAAB5E9A0FQ37477968-6373716B-FEA7-4D91-AC07-E258D06B344FQ37615093-B2C1E35E-FC7B-42E6-800A-CC89CD34B465Q37687469-005AC60A-579C-4974-A0E5-26B5EB5855BEQ37857548-F2105A00-59FE-402B-9D41-65EA8E669131Q38006981-7F5D77D6-9307-4958-8042-A0DC112C3107Q38187481-C36C0CD8-78A0-4832-9D7B-C1805C575974Q39204810-E6CD1FF0-E226-4F84-B239-DB10C7974EB6Q39310321-C35AA66A-35F9-4EBA-BA97-C3274E8295E6Q39410837-E3715B45-7B66-4647-94D6-7D7278B560E1Q39578956-376B2477-DBE5-401D-92A7-E4C8FF63EEADQ40043962-9071F230-2046-4362-AF95-1C50F9BE2B92Q40301234-F213BF5C-4EEE-489A-B9DB-8FB10CA06FB8Q42351179-259C3A71-485E-4AE0-B59A-459536221BCAQ42363950-6FF06450-790A-41D8-9E22-6AD9B1FE4A54Q42775457-F476DBA0-562B-4EC8-AFB3-A361FB44BD15Q43461278-5A217379-4B20-4442-B4E4-6681C8076616Q48261809-CF9E0477-F017-4CFC-A85D-455DD78DDFF7Q48801470-A3A65EA6-056D-42B7-A872-093C8AFC98FAQ49072801-904C051E-36DE-4ADB-87B9-9EACF4DD3138Q51833826-6224CD3F-F2A3-49E9-91F7-3AC01403A7B6
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
What makes placebo-controlled trials unethical?
@en
What makes placebo-controlled trials unethical?
@nl
type
label
What makes placebo-controlled trials unethical?
@en
What makes placebo-controlled trials unethical?
@nl
prefLabel
What makes placebo-controlled trials unethical?
@en
What makes placebo-controlled trials unethical?
@nl
P1476
What makes placebo-controlled trials unethical?
@en
P2093
Franklin G Miller
Howard Brody
P356
10.1162/152651602317533523
P577
2002-01-01T00:00:00Z